INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102
Non-Hodgkin's Lymphoma | Phase I
What is the purpose of this trial?
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC. Both intermediate risk and BCG-unresponsive NMIBC participants will be included.
- Trial withEisai Pharmaceuticals
- Start Date07/30/2020
- End Date10/31/2022
- Last Updated08/13/2020
- Study HIC#2000026758